Product Description
topical cytosolic phospholipase A2 inhibitor
Mechanisms of Action: Immunomodulator,PLA2 Modulator,TNF Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Avexxin AS
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Keratosis, Actinic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
COAKs | P2 |
Completed |
Keratosis, Actinic |
2022-03-11 |